Sumitomo Dainippon Pharma announces the Clinical Data of Investigational Anti-Cancer Agent Alvocidib will be presented at EHA2018

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that the clinical data for investigational inhibitor of cyclin-dependent kinase 9 (CDK9), alvocidib (generic name) will be presented at the poster session of the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm, Sweden from June 14 to June 17, 2018.

The abstract is now available on the official website of EHA.
(https://ehaweb.org/congress/23rd-c/key-information/)

Outline of poster presentation at the EHA

<table>
<thead>
<tr>
<th>Abstract number</th>
<th>Title of poster presentation</th>
<th>Date and Time, Location</th>
<th>Study number</th>
<th>Cancer Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF243</td>
<td>Phase II Study Incorporating a Novel BH3-Profiling Biomarker Approach of Alvocidib Followed by Cytarabine and Mitoxantrone in Relapsed/Refractory Acute Myeloid Leukemia (AML)</td>
<td>June 15, 2018 5:30 PM-7:00 PM (local time), Poster area</td>
<td>TPI-ALV-201 (NCT02520011)</td>
<td>Acute Myeloid Leukemia (AML)</td>
</tr>
</tbody>
</table>

(Reference)

【About inhibitor of cyclin-dependent kinase 9 (CDK9) alvocidib】
Alvocidib is a small molecule inhibitor of cyclin-dependent kinase 9 (CDK9), a member of cyclin-dependent kinase family, which activates transcription of cancer-related genes. The subsequent down-regulation of MCL-1, an anti-apoptotic gene, may be responsible for the potential clinical anti-cancer activity observed with alvocidib.

【About MCL-1(Myeloid Cell Leukemia 1)】
MCL-1 is an anti-apoptotic factor.

【About BH3-Profiling Biomarker】
B cell leukemia/lymphoma-2 (BCL-2) homology domain 3 (BH3) profiling is a functional assay to predict cellular dependence on anti-apoptotic proteins like BCL-2 or MCL-1.
* Alvocidib has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer or any other disorder.

Contact:
Public & Investor Relations Group, Corporate Governance
Sumitomo Dainippon Pharma Co., Ltd.
TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)